This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025.
The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to mitigate and/or treat tissue injuries from ionizing radiation exposure in a radiological or nuclear incident. The goal is to support research that can produce radiation medical countermeasures that are effective 24 hours or more after exposure, as strategic national stockpile drugs may not be mobilized that quickly. Awards of up to $4 million per year were available for one to two contractors. This contract with Meabco Inc. appears to be one of those awards.
Generated 1/17/25, 9:14 AM